Cowen Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $225.00

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) had its target price hoisted by investment analysts at Cowen from $200.00 to $225.00 in a research report issued to clients and investors on Thursday, Stock Target Advisor reports. Cowen’s price target would suggest a potential upside of 47.41% from the company’s previous close.

Several other research firms also recently issued reports on JAZZ. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 2nd. StockNews.com raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 26th. BMO Capital Markets decreased their target price on shares of Jazz Pharmaceuticals from $202.00 to $187.00 in a research report on Wednesday, March 2nd. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $180.00 to $200.00 in a research report on Thursday, January 20th. Finally, Cowen increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $206.47.

Jazz Pharmaceuticals stock opened at $152.64 on Thursday. The business has a 50 day moving average of $158.97 and a 200-day moving average of $142.74. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $189.00. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 1.52.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.73. Jazz Pharmaceuticals had a positive return on equity of 21.88% and a negative net margin of 13.63%. The company had revenue of $813.72 million during the quarter, compared to the consensus estimate of $853.73 million. During the same quarter in the prior year, the firm posted $3.42 earnings per share. The firm’s revenue was up 33.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Jazz Pharmaceuticals will post 13.55 EPS for the current year.

In related news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction on Monday, April 4th. The stock was sold at an average price of $158.33, for a total value of $1,705,530.76. Following the transaction, the chief executive officer now directly owns 346,062 shares in the company, valued at approximately $54,791,996.46. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 7,260 shares of the stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $156.63, for a total value of $1,137,133.80. Following the completion of the transaction, the chief executive officer now owns 348,502 shares in the company, valued at $54,585,868.26. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Great Lakes Advisors LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $270,000. Los Angeles Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 4.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 45,287 shares of the specialty pharmaceutical company’s stock valued at $7,050,000 after acquiring an additional 1,903 shares in the last quarter. Balentine LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $258,000. Cordatus Wealth Management LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $1,214,000. Finally, State Board of Administration of Florida Retirement System lifted its stake in Jazz Pharmaceuticals by 0.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 66,467 shares of the specialty pharmaceutical company’s stock valued at $10,347,000 after acquiring an additional 236 shares in the last quarter. Institutional investors own 93.23% of the company’s stock.

About Jazz Pharmaceuticals (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Read More

Stock Target Advisor logo

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.